Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 May 2024.Powered by Capital Market - Live News

Alembic Pharmaceuticals has received US Food & Drug administration (USFDA) Product Approval (Tentative) for Ribociclib Tablets, 200 mg. Ribociclib tablet indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy. Alembic has a cumulative total of 197 ANDA approvals (170 final approvals and 27 tentative approvals) from USFDA. Powered by Capital Market - Live News

Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has conducted an inspection at its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28 February 2024 to 8 March 2024. The US FDA issued a Form 483 with four procedural observations.The Company will provide comprehensive response to USFDA for the observations within the stipulated period.Powered by Capital Market - Live News

Net profit of Alembic Pharmaceuticals rose 48.01% to Rs 180.45 crore in the quarter ended December 2023 as against Rs 121.92 crore during the previous quarter ended December 2022. Sales rose 8.05% to Rs 1630.57 crore in the quarter ended December 2023 as against Rs 1509.02 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales1630.571509.02 8 OPM %16.3315.58 - PBDT254.04221.00 15 PBT184.59154.49 19 NP180.45121.92 48 Powered by Capital Market - Live News

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 February 2024.Powered by Capital Market - Live News